Acumen Pharmaceuticals (ABOS) Other Non-Current Liabilities (2023 - 2025)

Acumen Pharmaceuticals (ABOS) has 3 years of Other Non-Current Liabilities data on file, last reported at $39000.0 in Q3 2025.

• For the quarter ending Q3 2025, Other Non-Current Liabilities changed N/A year-over-year to $39000.0; the trailing twelve-month figure through Sep 2025 stood at $39000.0 (changed N/A YoY), and the FY2024 full-year result was $150000.0, down 47.18% from the prior year.
• Other Non-Current Liabilities retreated to $39000.0 in Q3 2025, from $77000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $284000.0 in Q4 2023 to a low of $39000.0 in Q3 2025.
• A 3-year average of $132800.0 and a median of $114000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
• Peak annual rise in Other Non-Current Liabilities reached 47.18% in 2024, while the deepest fall reached 47.18% in 2024.
• Tracing ABOS's Other Non-Current Liabilities over 3 years: stood at $284000.0 in 2023, then slumped by 47.18% to $150000.0 in 2024, then slumped by 74.0% to $39000.0 in 2025.
• Business Quant data shows ABOS's Other Non-Current Liabilities at $39000.0 in Q3 2025, $77000.0 in Q2 2025, and $114000.0 in Q1 2025.